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Impact of Antihypertensive Treatment on Maternal and Perinatal
Outcomes in Pregnancy Complicated by Chronic Hypertension:
A Systematic Review and Meta-Analysis
Louise M. Webster, BMBS, BMedSci; Frances Conti-Ramsden, MA, MBBS; Paul T. Seed, CStat; Andrew J. Webb, MBBS, PhD, FRCP;
Catherine Nelson-Piercy, MBBS, MA; Lucy C. Chappell, BMBCh, PhD
Background-—Chronic hypertension complicates around 3% of all pregnancies. There is evidence that treating severe hypertension
reduces maternal morbidity. This study aimed to systematically review randomized controlled trials of antihypertensive agents
treating chronic hypertension in pregnancy to determine the effect of this intervention.
Methods and Results-—Medline (via OVID), Embase (via OVID) and the Cochrane Trials Register were searched from their earliest
entries until November 30, 2016. All randomized controlled trials evaluating antihypertensive treatments for chronic hypertension
in pregnancy were included. Data were extracted and analyzed in Stata (version 14.1). Fifteen randomized controlled trials (1166
women) were identiﬁed for meta-analysis. A clinically important reduction in the incidence of severe hypertension was seen with
antihypertensive treatment versus no antihypertensive treatment/placebo (5 studies, 446 women; risk ratio 0.33, 95%CI 0.19-
0.56; I2 0.0%). There was no difference in the incidence of superimposed pre-eclampsia (7 studies, 727 women; risk ratio 0.74, 95%
CI 0.49-1.11; I2 28.1%), stillbirth/neonatal death (4 studies, 667 women; risk ratio 0.37, 95%CI 0.11-1.26; I2 0.0%), birth weight (7
studies, 802 women; weighted mean difference 60 g, 95%CI 200 to 80 g; I2 0.0%), or small for gestational age (4 studies, 369
women; risk ratio 1.01, 95%CI 0.53-1.94; I2 0.0%) with antihypertensive treatment versus no treatment/placebo.
Conclusions-—Antihypertensive treatment reduces the risk of severe hypertension in pregnant women with chronic hypertension.
A considerable paucity of data exists to guide choice of antihypertensive agent. Adequately powered head-to-head randomized
controlled trials of commonly used antihypertensive agents are required to inform prescribing. ( J Am Heart Assoc. 2017;6:
e005526. DOI: 10.1161/JAHA.117.005526.)
Key Words: antihypertensive agent • hypertension • meta-analysis • pregnancy • systematic review
C hronic hypertension complicates around 3% of allpregnancies.1,2 There is growing evidence that the
incidence is rising with increasing maternal age and obe-
sity.2-5 The increased risks of adverse perinatal outcomes for
pregnant women with chronic hypertension are well estab-
lished.6,7 In addition, controlling severe systolic hypertension
has been recommended repeatedly by national and
international guidance to reduce the risks of maternal
morbidity and mortality.8-10
There remains some debate regarding the efﬁcacy of
treating chronic hypertension in pregnancy before it reaches
severe levels due to concerns for fetal growth.11-16 Interna-
tionally, guidelines vary for the management of chronic
hypertension in pregnancy.17 However, the Control of Hyper-
tension in Pregnancy Study, published in 2015, reported that
there was no effect of tight blood pressure control (target
diastolic 85 mm Hg) compared to less tight control (target
diastolic 105 mm Hg) on a composite outcome of pregnancy
loss and high-level neonatal care within the ﬁrst 48 hours of
infant life (31.4% versus 30.7%) and the overall risk of small-
for-gestational-age infants (birth weight <10th centile) was
not different between groups (16.1% versus 19.7%; odds ratio
0.78, 95%CI 0.56-1.08). The frequency of severe hypertension
was signiﬁcantly higher with less-tight control compared with
tight control (40.6% versus 27.5%; odds ratio 1.8, 95%CI 1.3-
2.4).18 There are likely to be additional beneﬁts of reducing
the incidence of severe hypertension through a decrease in
short- and long-term maternal morbidity and mortality from
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stroke and other end-organ damage9,19-22 and potential cost
savings with a reduction in healthcare resource use.23,24
Given the physiological demands of pregnancy, duration of
treatment and potential impacts on maternal and perinatal
outcomes, there is a need for evidence on efﬁcacy and safety
of antihypertensive treatment speciﬁcally in pregnancy com-
plicated by chronic hypertension. Current international guid-
ance points to the lack of evidence for antihypertensive agent
prescribing in chronic hypertension in pregnancy.8,17 Because
the beneﬁts of tight-control blood pressure targets have now
been demonstrated in women with hypertension in pregnancy,
this study aimed to systematically review and meta-analyze
available data from randomized controlled trials speciﬁcally in
chronic hypertension to establish the efﬁcacy and safety of
antihypertensive agents or class of agents.
Methods
The study protocol for this systematic review was developed
in line with the PRISMA-P statement25 and registered on the
PROSPEROdatabase (http://www.crd.york.ac.uk/PROSPERO/
reference number CRD42015020733). No ethical approval
was required.
Literature Search
A comprehensive literature review using Medline (via Ovid),
Embase (via Ovid), and the Cochrane Trials Register from their
earliest entries until the November 30, 2016 was performed.
Search strategies were adapted to each database. Searches
of exploded MeSH terms “pregnancy,” “hypertension,” and
“antihypertensive” (Embase) or “cardiovascular agent” (Med-
line) were performed individually and then combined in each
database. For Medline and Embase searches, a search ﬁlter
for randomized controlled trials was then applied as recom-
mended in the Cochrane Handbook for Systematic Reviews of
Interventions.26 Relevant unpublished data were sought by
searching for trials registered on clinicaltrials.gov and ISRCTN
(www.isrctn.com) and reviewing thesis titles from the World
Cat dissertations and theses database. References of
retrieved studies and relevant review articles were also
searched using the snowballing approach. No language
restrictions were applied. The study protocol (including the
literature search strategy) is detailed in Data S1.
Study Selection Criteria
All randomized controlled trials of pregnant womenwith chronic
hypertension comparing an antihypertensive agent with
another treatment arm as long-term antepartum management
were included. No blood pressure cutoffs were utilized in the
eligibility criteria for inclusion, but studies examining acute
treatment of severe hypertension via intravenous/fast-acting
routes were excluded. Comparisons with other antihyperten-
sive drug(s), placebo, no treatment, or an alternative such as
bed rest were eligible for inclusion. Studies that included
participants with gestational hypertension and chronic hyper-
tension were only eligible for inclusion if the data for the women
with chronic hypertensionwere reported separately to allow fair
comparison. Studies that compared management strategies
only but did not include a randomized comparison of drug
treatments were not eligible for inclusion. Trials that did not
report any of the predeﬁned outcomes were excluded. Trials
that did not include sufﬁcient information on the outcomes (eg,
standard deviations) could not be included in themeta-analysis.
No other restrictions were applied to the study search.
Data Extraction
The titles, abstracts and selected full texts generated from the
literature search were independently screened by authors
L.M.W. and F.C.R. Data from the trials that met all inclusion
criteria were manually extracted and entered into a standard
extraction table independently from full texts by L.M.W. and
F.C.R. The authorswere notmasked to the results of the study or
authors.Where 2 articles published results from the same study,
individual pertinent outcomes were extracted from both articles
without repetition of data extraction. The following outcome
measures were recorded for each study: maternal, severe
hypertension (deﬁnitions used in each study documented),
superimposed pre-eclampsia (deﬁnitions used in each study
documented), cesarean section delivery, abruption; perinatal,
stillbirth/neonatal death, birth weight, small-for-gestational-age
infants (within trial deﬁnition), pretermbirth (deﬁned as less than
37 completed weeks’ gestation), and Apgar score less than 7 at
5 minutes. Details of potential confounders (maternal age, body
mass index, ethnicity) were recorded wherever provided in the
manuscripts. The PRISMA statement was considered and
observed for all procedures and reporting.27
Study Quality Assessment
Each trial was independently quality assessed using the
Cochrane Collaboration Risk of Bias tool by L.M.W. and
F.C.R.26 The risk of bias in each of the following domains was
assessed: sequence generation, allocation concealment,
blinding, incomplete outcome data, selective outcome report-
ing, and other sources of bias.
Statistical Methods
Data were analyzed in the statistical package Stata (version
14.1, StataCorp, College Station, TX), using the metan suite
DOI: 10.1161/JAHA.117.005526 Journal of the American Heart Association 2
Treatment of Chronic Hypertension in Pregnancy Webster et al
S
Y
S
T
E
M
A
T
IC
R
E
V
IE
W
A
N
D
M
E
T
A
-A
N
A
L
Y
S
IS
 by guest on M
ay 17, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
of commands.28 All outcomes were analyzed on an intention-
to-treat basis. Per-protocol data for an end point were
excluded from the analysis. Meta-analysis was performed
using a ﬁxed-effects model where there was more than 1
study with analyzable data. If there was evidence of
signiﬁcant heterogeneity, the meta-analysis was repeated
using the random-effects model for comparison; however,
the results presented are from the ﬁxed-effects analysis.
Initial analysis of treatment effects was performed by class
of antihypertensive agent and subsequently by active versus
nonactive treatment. Treatment effects are presented as
estimated differences in mean or risk ratios with 95%
conﬁdence intervals. Heterogeneity was quantiﬁed via the s-
squared and I-squared statistics.29
Results
Description of Studies
The study selection process is illustrated in the ﬂowchart
(Figure 1). After removal of duplicates, the initial search
generated 501 titles and abstracts for review. Following
screening, 39 articles underwent full-text assessment. Sixteen
articles met inclusion criteria, reporting on 15 trials that
recruited a total of 1166 women, with a median of 20
participants per trial (interquartile range 12-60 participants
per trial). The characteristics of the studies meeting entry
criteria are presented in Table 1.
All studies included in the meta-analysis were completed
before 1998. Ten of the trials were conducted in a predeﬁned
chronic hypertension cohort alone,* and the remaining 5
reported outcomes for a subgroup of women with chronic
hypertension.32,35,37-39,43 Six studies were head-to-head
comparisons of 2 or more antihypertensive agents (435
women),32,33,35,41,43,45 4 were placebo-controlled studies of a
single antihypertensive agent (219 women),31,34,42,44 and 5
were studies of a single antihypertensive agent compared to
no treatment (714 women).30,36-40
Of the 23 articles that were excluded, 14 studies included
a mixed population of gestational and chronic hypertension
and did not report outcomes separately, 6 studies included
Records idenƟfied through 
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Medline=269
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Figure 1. Flowchart of articles identiﬁed reporting randomized controlled trials of antihypertensive
agents for the treatment of chronic hypertension in pregnancy.
*References 30, 31, 33, 34, 36, 40-42, 44, 45.
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Table 1. Characteristics of the Studies Included in the Meta-Analysis
Study First
Author,
Country, Year Methods
Participants With Chronic
Hypertension Intervention
Outcomes Included in
Meta-Analysis
Arias,
USA,
197930*
 Participants allocated
randomly to antihyper-
tensive treatment or no
treatment
 No allocation
concealment
 58 women
 History of hypertension
before pregnancy
(BP >140/90 mm Hg)
 OR hypertension in 2
consecutive measurements
more than 24 h apart
at <20 weeks’ gestation
 AND diastolic BP <100 mm Hg
and no end organ damage
Excluded:
 Nulliparous women
 Major obstetric or medical
problem, eg, diabetes mellitus
 >20 weeks’ gestation
Active:
A varied combination of:
 Methyldopa 750 to
2000 mg/day
 AND/OR hydralazine 75 to
250 mg/day
 AND/OR hydrochlorothiazide
50 mg/day
Vs nonactive:
 No treatment
Maternal:
 Severe hypertension
 Superimposed pre-
eclampsia
 Mode of delivery
Perinatal:
 Stillbirth/neonatal death
 Birth weight
 Preterm birth
Butters,
UK,
199031
 Double-blind
randomized
controlled trial
 29 women
 Systolic BP 140 to
170 mm Hg OR diastolic
BP 90 to 110 mm Hg on 2
occasions separated by at
least 24 h between 12
and 24 weeks’ gestation in
women with known
essential hypertension
Excluded:
 Contra-indication to b-blocker
Active:
 Atenolol 50 to 200 mg/day
Vs nonactive:
 Placebo tablets
Perinatal:
 Stillbirth
 Birth weight
 Small for gestational age
Fiddler,
UK,
198332
 Participants mixed
population of
gestational and
chronic hypertension
 Stratified randomization
 Open label
 46 women
 Diastolic BP >95 mm Hg
on 2 occasions at least
24 h apart <32 weeks’
gestation
 OR diastolic
BP >105 mm Hg on 1
occasion at <32 weeks’
gestation
Excluded:
 Diabetes mellitus
 Multiple pregnancy
 Already taking
antihypertensive treatment
 Significant medical condition
Active:
 Methyldopa 750 to
3000 mg/day
Vs active:
 Oxprenolol 160 to 640 mg/day
Maternal:
 Severe hypertension
 Mode of delivery
Perinatal:
 Birth weight
 Apgar score
<7 at 5 min
Freire,
Brazil,
198833
 Consecutive
randomization
allocation
 No information on
allocation concealment
 40 women
 Known chronic hypertension
 Diastolic BP >95 mm Hg
Active:
 Methyldopa 250 to
2000 mg/day
Maternal:
 Severe hypertension
 Superimposed pre-
eclampsia
Continued
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Table 1. Continued
Study First
Author,
Country, Year Methods
Participants With Chronic
Hypertension Intervention
Outcomes Included in
Meta-Analysis
Excluded:
 Proteinuria at study entry
 End-organ disease
Vs active:
 Pindolol 10 to 30 mg/day
Perinatal:
 Stillbirth
 Birth weight
 Apgar score
<7 at 5 min
Hirsch,
Israel,
199634
 Randomized using
serial numbers in
blocks of 6
 No information on
allocation concealment
 27 women
 Elevated BP before
pregnancy or diastolic
BP 85 to 99 mm Hg
at <20 weeks’ gestation
Excluded:
 Known medical or obstetric
complication that could affect
pregnancy outcome
 b-blockers contraindicated
Active:
 Pindolol 10 to 20 mg/day
Vs non-active:
 Placebo tablets
Maternal:
 Severe hypertension
Perinatal:
 Birth weight
 Small for gestational age
 Apgar score
<7 at 5 min
Horvath,
Australia,
198535
 Participants mixed
population of
gestational and chronic
hypertension
 Double-blind,
randomized trial
 Participants entered
in numerical sequence
 16 women
 Known essential
hypertension
 OR failure of hypertension
to resolve 12 weeks
postpartum from
previous pregnancy
 OR BP >130/85 mm Hg
on 2 or more occasions
Active:
 Methyldopa 250 to
2000 mg/day
Vs nonactive:
 Clonidine 150 to 1200 lg/day
Perinatal:
 Stillbirth/neonatal death
Kahhale,
Brazil, 198536
 Women divided into
2 groups—treatment
and control
 No information regard-
ing
concealment
 100 women
 BP >140/90 mm Hg
before 20 weeks’ gestation
Excluded:
 Proteinuria at study entry
 Contraindication to
b-blockers
Active:
 Pindolol 10 to 30 mg/day
Vs nonactive:
 No treatment
Perinatal:
 Stillbirth
 Birth weight
 Apgar score
<7 at 5 min
Mutch,
UK, 197737†
 Participants mixed
population of
gestational and chronic
hypertension
 Randomly allocated
 Open label
 202 women
 BP >140/90 mm Hg on 2
occasions at least 24 h apart
before 28 weeks’ gestation
Excluded:
 BP at study
entry >170 mm Hg
systolic or >110 mm Hg
diastolic
 Multiple pregnancy
 Rhesus incompatibility
 Severe maternal disease
Active:
 Methyldopa—dosing
regimen not specified
Vs nonactive:
 No treatment
Maternal:
 Severe hypertension
 Superimposed
pre-eclampsia
 Mode of delivery
Continued
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Table 1. Continued
Study First
Author,
Country, Year Methods
Participants With Chronic
Hypertension Intervention
Outcomes Included in
Meta-Analysis
Parazzini,
Italy, 199838
 Participants mixed
population of
gestational and
chronic hypertension
 Computer-generated
randomization list
 Open label
 126 women
 Known chronic
hypertension before
pregnancy with 2
consecutive diastolic
BP >90 mm Hg
 OR diastolic BP >90 mm Hg
before 20 weeks’ gestation
Excluded:
 Chronic disease, eg,
diabetes mellitus, renal
disease
 Fetal malformations
 Already on
antihypertensive treatment
 Contraindications to
nifedipine
Active:
 Nifedipine slow release
20 to 80 mg/day
Vs nonactive:
 No treatment
Perinatal:
 Birth weight
Redman,
UK, 197639†
 Participants mixed
population of
gestational and
chronic hypertension
 Allocated randomly
to treatment group
 Open label
 208 women
 BP >140/90 mm Hg on
2 occasions at least
24 h apart before
28 weeks’ gestation
Excluded:
 Severe hypertension at study
entry (systolic BP
>170 mm Hg or
diastolic BP >110 mm Hg)
 Already on antihypertensive
treatment
 Multiple pregnancy
 Diabetes mellitus
 Rhesus immunisation
Active:
 Methyldopa—dosing
regimen not specified
Vs nonactive:
 No treatment
Perinatal:
 Stillbirth/neonatal death
 Birth weight
Sibai, USA,
198440
 Participants taking
diuretics randomized
to continue or
discontinue treatment
 Open label
 20 women
 Long-term history of
hypertension, diastolic
BP >90 and <110 mm Hg
 Receiving diuretics before
pregnancy
Active:
 Diuretics—specific agent(s)
and doses not specified
Vs nonactive:
 No treatment (diuretics
discontinued)
Maternal:
 Superimposed
pre-eclampsia
 Mode of delivery
Perinatal:
 Birth weight
 Preterm birth
 Apgar score
<7 at 5 min
Continued
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Table 1. Continued
Study First
Author,
Country, Year Methods
Participants With Chronic
Hypertension Intervention
Outcomes Included in
Meta-Analysis
Sibai,
USA,
199041
 Computer-generated
randomization via
list of numbers
 Open label
 263 women
 History of chronic
hypertension prior
to pregnancy
Excluded:
 Medical complications other
than chronic hypertension
Active:
 Methyldopa 750 to
4000 mg/day
Vs active:
 Labetalol 300 to 2400 mg/day
Vs nonactive:
 No treatment
Maternal:
 Superimposed
pre-eclampsia
 Mode of delivery
 Abruption
Perinatal:
 Stillbirth/neonatal death
 Birth weight
 Preterm birth
 Apgar score
<7 at 5 min
Steyn,
South Africa,
199742
 Double-blind
randomized
placebo-controlled trial
 Computer-generated
randomization
numbers, using
balanced-block method
 138 women
 Diastolic BP persistently
>80 mm Hg between
12 and 20 weeks’
gestation without
proteinuria
Excluded:
 Multiple pregnancy
 Bradycardia on ECG
Active:
 Ketanserin 40 to 80 mg/day
Vs nonactive:
 Placebo tablets
Maternal:
 Severe hypertension
 Superimposed
pre-eclampsia
 Abruption
Perinatal:
 Stillbirth/neonatal death
Voto, Argentina,
199043
 Participants mixed
population of
gestational and chronic
hypertension
 Randomized
comparative study
 Open label
 49 women
 Known chronic hypertension
with BP >159/99 mm Hg
twice 24 h apart
Excluded:
 Women requiring more than
1 drug to control BP
Active:
 Atenolol 50 to 200 mg/day
Vs active:
 Methyldopa 500 to
2000 mg/day
Vs active:
 Ketanserin 80 to 120 mg/day
Maternal:
 Superimposed
pre-eclampsia
Weitz, USA,
198744
 Double blind
randomized study
 25 women
 Chronic hypertension,
BP 140/90 mm Hg on
2 occasions >6 h
apart
 No proteinuria
 Singleton pregnancies
 <34 weeks’ gestation
Active:
 Methyldopa 750 to 2000 g/day
Vs nonactive:
 Placebo tablets
Maternal:
 Superimposed
pre-eclampsia
Perinatal:
 Stillbirth/neonatal death
Welt, USA,
198145
 Prospective cohort
study with subgroup
randomized to
treatment
 Not clear if either
clinician and/or
participant blinded to
treatment allocation
 21 women
 With documented
prepregnancy history
of elevated BP >140/
90 mm Hg on 2 occasions
>6 h apart
 OR in first 2 trimesters
of pregnancy
Active:
 Methyldopa 750 mg/day—
maximum dose not given
Vs active:
 Hydralazine 75 mg/day—
maximum dose not given
Maternal:
 Severe hypertension
 Superimposed
pre-eclampsia
Perinatal:
 Small for gestational age
Continued
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only gestational hypertension, 1 article reported no additional
outcomes for a trial already included in the meta-analysis
(Table 2).46-68 In addition, Leather and colleagues reported a
randomized controlled trial in 1968 that recruited 47 chronic
hypertensive participants randomized to bendroﬂumethiazide
and methyldopa versus no treatment. This article could not be
included due to inadequate reporting of the statistical
information relating to the outcomes, prohibiting inclusion
of the data in the meta-analysis.58 Leather and colleagues
concluded that the treatment of “early hypertension” (present
before 20 weeks’ gestation) resulted in a longer pregnancy,
increased birth weight and reduced perinatal mortality. A pilot
study by Vigil-De Gracia and colleagues in 2014 compared
furosemide, amlodipine, and aspirin in a 3-arm randomized
controlled trial and found no signiﬁcant difference in
outcomes among all treatment arms.65 These data could
not be included in the active versus nonactive treatment
meta-analysis, as the third arm of aspirin was considered
active treatment given that the other arms did not receive this
agent. In addition, the data from the amlodipine and
furosemide arms could not be included in the antihyperten-
sive treatment versus antihypertensive treatment meta-
analysis as there are no other head-to-head trials evaluating
calcium-channel blockers or diuretics for comparison.
Deﬁnitions of severe hypertension and superimposed pre-
eclampsia for each included study are listed in Table 3.
Minimum diastolic and systolic blood pressure eligibility
cutoffs ranged from 80 to 99 and 140 to 160 mm Hg,
respectively. Two studies excluded women with protein-
uria,33,44 3 studies included women with proteinuria at study
entry,32,35,43 and the remainder of studies did not specify
presence or absence of proteinuria in their methods. Six
studies excluded multifetal pregnancies30,32,40,41,44,45; the
remainder either included women with multifetal pregnancies
or did not specify inclusion or exclusion in their methods.
Maternal age was the only potential confounding baseline
characteristic consistently reported. This ranged from 28 to
33 years, and no adjustment was deemed pertinent to this
analysis. Body mass index was not reported in any of the
trials, but 6 studies reported maternal weight at trial entry.
Ethnicity of the participants was not considered or recorded in
any of the trials.
Risk of Bias in Included Studies
All studies were assessed to be at high risk of bias apart from
Steyn and colleagues,42 which was assigned unclear risk of
bias. Full details of the allocated risk-of-bias scoring are
displayed in Figure 2. No formal assessment of socioeco-
nomic settings of the studies was made given the small
number of studies, but all were from middle- or high-income
countries (see Table 1).
Effects of Intervention: Active Versus Nonactive
Treatment
Antihypertensive treatment reduces the incidence of severe
hypertension in pregnancy complicated by chronic hyperten-
sion compared with no antihypertensive or placebo, with a
risk ratio of 0.33 (95%CI 0.19-0.56), based on 446 women
from 5 studies. The risk of superimposed pre-eclampsia was
not signiﬁcantly different between those randomized to active
versus nonactive treatment; risk ratio 0.74 (95%CI 0.49-1.11:
727 women, 7 studies) (Figure 3).
Table 1. Continued
Study First
Author,
Country, Year Methods
Participants With Chronic
Hypertension Intervention
Outcomes Included in
Meta-Analysis
 OR undocumented history
of hypertension for which
the patient was taking
antihypertensive treatment
before or during pregnancy
Excluded:
 Diabetes mellitus
requiring insulin
 Multiple pregnancy
 Planning to terminate
pregnancy
Vs nonactive:
 Placebo tablets
BP indicates blood pressure.
Participants randomized to antihypertensive treatment (not to an agent) vs no antihypertensive treatment.30
†Articles reporting on the same study population.
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Table 2. Studies Excluded From the Meta-Analysis and Rationale
Study (First Author, Country,
Year Published) Reason for Exclusion and Study Details
Antony, South Africa, 199046 Study participants had gestational and not chronic hypertension
Methods: Prospective, randomized block design, no further details given
Participants: 60 women at 28 to 36 weeks’ gestation with mean 24-h diastolic BP 100 to 120 mm
Hgproteinuria
Intervention: Indoramin 50 mg twice daily vs methyldopa 1 g twice daily vs placebo 1 tablet daily
Bolte, Netherlands, 199847 Study participants had gestational or chronic hypertension. Outcomes for those with chronic hypertension
not reported separately
Methods: Randomized, open-label multicenter trial
Participants: 31 women, 26 to 32 weeks’ gestation with diastolic BP >110 mm Hg and previously normotensive
or in women with chronic hypertension: diastolic BP >20 mm Hg compared to BP at <20 weeks.
Intervention: IV ketanserin 5 mg bolus then 4 mg/h vs IV dihydralazine 1 mg/h
Bott-Kanner, Israel, 199248 Study participants had gestational or chronic hypertension. Outcomes for those with chronic hypertension
not reported separately
Methods: Randomized, double-blind trial. Women randomized in blocks of 6 using serial numbers
Participants: 60 women before 35 weeks’ gestation with diastolic BP 85 to 99 mm Hg
Intervention: Pindolol 5 mg twice daily or placebo 1 tablet twice daily
Cruickshank, UK, 199149 Study participants had gestational and not chronic hypertension
Methods: Randomized open-label trial, using numbered sealed envelopes
Participants: 114 women with singleton pregnancies between 24 and 39 weeks’ gestation, diastolic
BP >90 mm Hg for >24 h in absence of proteinuria
Intervention: Labetalol 100 mg twice daily vs no treatment
Faneite, Venezuela, 198850 Study participants had gestational or chronic hypertension. Outcomes for those with chronic hypertension
not reported separately
Methods: Randomized trial
Participants: 31 women >14 weeks’ gestation, with BP >140/90 and <170/110 mm Hg on 2 occasions
Intervention: Mepindolol 5 mg once daily vs methyldopa 250 mg twice daily
Gallery, Australia, 197951 Study participants had gestational or chronic hypertension. Outcomes for those with chronic hypertension
not reported separately
Methods: Randomized comparison study
Participants: 56 women at any gestation with sitting diastolic BP >95 mm Hg on 2 occasions at least 24 h
apart or 100 mm Hg on 2 occasions at least 8 h apart
Intervention: Oxprenolol vs methyldopa. Doses not specified
Gallery, Australia, 198552 Study participants had gestational or chronic hypertension. Outcomes for those with chronic hypertension
not reported separately
Methods: Randomized open study, allocation by random number series
Participants: 183 women with singleton pregnancies and sitting diastolic BP of >90 mm Hg on 2 occasions at least
24 h apart or >95 mm Hg on 2 occasions 12 h apart or >100 mm Hg on 2 occasions 8 h apart
Intervention: Oxprenolol 40 mg twice daily vs methyldopa 250 mg twice daily
Hall, South Africa, 200053 Study participants had pre-eclampsia or gestational or chronic hypertension. Outcomes for those with chronic
hypertension not reported separately
Methods: Randomized single-blind controlled trial. Computer-generated balanced blocks of 50 numbers. Women
allocated using consecutive numbered, opaque envelopes containing medication
Participants: 150 women with severe early-onset pre-eclampsia or hypertension and BP not controlled with
methyldopa 2 mg daily
Intervention: Nifedipine 10 mg 3 times daily vs prazosin 1 mg 3 times daily
Henderson-Smart, Australia,
198454
Details of participants with chronic hypertension not stated
Methods: Reporting neonatal outcomes of infants born to women with hypertension in pregnancy who were entered
in a prospective randomized double-blind trial
Participants: 95 infants born to mothers treated with clonidine hydrochloride and methyldopa
Intervention: Clonidine hydrochloride 150 to 1200 lg/day vs methyldopa 250 to 2000 mg/day
Continued
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Table 2. Continued
Study (First Author, Country,
Year Published) Reason for Exclusion and Study Details
H€ogstedt, Sweden, 198555 Study participants had gestational or chronic hypertension. Outcomes for those with chronic hypertension
not reported separately
Methods: Randomized open controlled trial
Participants: 161 women in antenatal care with diastolic BP >90 mm Hg on 2 occasions at least 6 h apart,
confirmed the following day with diastolic BP >90 mm Hg for at least 2 out of 4 BP readings
Intervention: 50 mg metoprolol and 25 mg hydralazine twice daily vs no treatment
Jannet, France, 199456 Study participants had gestational or chronic hypertension or pre-eclampsia. Outcomes for those with chronic
hypertension not reported separately
Methods: Randomized comparative trial. Computer-generated random numbers, allocated using sealed envelopes
Participants: 100 women with singleton pregnancies at >20 weeks’ gestation with systolic BP >140 mm Hg and/or
diastolic BP >90 mm Hg on 2 successive measurements
Intervention: Nicardipine 20 mg 3 times daily vs slow-release metoprolol 200 mg once daily
Lardoux, France, 198857 Study participants had gestational or chronic hypertension. Outcomes for those with chronic hypertension not
reported separately
Methods: Randomized open comparative trial
Participants: 63 women between 7 and 36 weeks’ gestation with diastolic BP >90 mm Hg on 2 occasions at least
8 days apart
Intervention: Methyldopa 500 mg/day vs labetalol 400 mg/day vs acebutolol 400 mg/day
Leather, UK, 196858 Outcome data not presented with adequate statistical information to allow inclusion in the meta-analysis
Methods: Randomized controlled trial
Participants: 100 women with diastolic BP >90 mm Hg on 2 occasions at least 48 h apart
Intervention: Bendroflumethiazide 5 to 10 mg daily and methyldopa 400 to 2000 mg daily vs no treatment
Livingstone, Australia,
198359
Study participants had gestational and not chronic hypertension
Methods: Randomized prospective study, no further details given
Participants: 28 women with BP >140/90 mm Hg on 2 consecutive readings at least 24 h apart
Intervention: Propranolol vs methyldopa. Doses not specified
Moore, UK, 198260 Study participants had gestational or chronic hypertension. Outcomes for women with chronic hypertension
not reported separately
Methods: Randomized trial, no further details given
Participants: 74 women at <36 weeks’ gestation with systolic BP >170 mm Hg and/or diastolic BP >110 mm Hg
Intervention: Labetalol 100 mg 4 times daily vs 250 mg methyldopa 4 times daily
Plouin, France, 198861 Study participants had gestational or chronic hypertension. Outcomes for women with chronic hypertension
not reported separately
Methods: Randomized open controlled trial. Stratified randomization using blinded envelopes
Participants: 176 women with a singleton pregnancy, gestational age between 12 and 34 weeks and diastolic BP
>89 mm Hg on 2 separate occasions
Intervention: Labetalol 400 mg in 2 doses vs methyldopa 500 mg in 2 doses
Rosenfeld, Israel, 198662 Study participants had gestational or chronic hypertension. Outcomes for those with chronic hypertension
not reported separately
Methods: Randomized study, no further details given
Participants: 44 women at <36 weeks’ gestation with systolic BP >150 mm Hg or diastolic BP >90 mm Hg on 2
separate occasions at least 24 h apart
Intervention: Hydralazine 25 mg twice daily vs hydralazine 25 mg twice daily and pindolol 5 mg twice daily
Steyn, South Africa, 200163 Reporting data from same trial as Steyn 1997,42 reported no additional outcomes
Methods: Randomized double blind controlled trial. Computer-generated balanced-block structure
Participants: 102 women between 12 and 20 weeks’ gestation with diastolic BP >80 mm Hg without proteinuria
Intervention: Ketanserin 20 mg twice daily and aspirin 75 mg once daily vs placebo 1 tablet twice daily and aspirin
75 mg once daily
Tuimala, Finland, 198864 Study participants had gestational and not chronic hypertension
Methods: Randomized trial, no further details given
Participants: 51 women with BP >149/94 mm Hg measured twice in sitting position after 2 days’ bed rest in
hospital
Intervention: Atenolol 50 to 100 mg/day vs pindolol 10 to 20 mg/day. If needed, hydralazine 150 mg/day added
Continued
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Perinatal outcomes were assessed to determine the
potential fetal and neonatal risks associated with antihyper-
tensive use when compared to nonactive treatment. The
analysis of stillbirth and neonatal death demonstrated a
nonsigniﬁcant reduction with the use of antihypertensive
treatment: risk ratio 0.37 (95%CI 0.11-1.26: 667 women, 4
studies). Birth weight was not signiﬁcantly different when
active versus nonactive treatments were compared (60 g
weighted mean difference, 95%CI 200 to 80 g: 802 women,
7 studies). There was no difference in small-for-gestational-
age infants with the use of antihypertensive agents (risk ratio
1.01, 95%CI 0.53-1.94: 369 women, 4 studies) (Figure 4). A
single study by Butters and colleagues comparing atenolol to
placebo found a signiﬁcant reduction in birth weight and
increase in small-for-gestational-age infants in the active
treatment arm.31 Given the degree of heterogeneity, these
results were explored further with the Egger test. This
demonstrated the Butters study31 to be an outlier (Figure 5).
When this study was included in the meta-analysis, weighted
mean difference in birth weight did not reach signiﬁcance,
100 g (95%CI 240 to 40 g; I2 49.6%) and similarly
although the risk of small-for-gestational-age birth weight
increased, it was not signiﬁcant (risk ratio 1.58, 95%CI l 0.88-
2.85; I2 38.6%).
The additional maternal and perinatal outcomes meta-
analyzed between active and nonactive arms are listed in
Table 4. There were no additional signiﬁcant differences.
Effects of Intervention: Antihypertensive Agent
Versus Antihypertensive Agent
Due to the small number of studies, comparison of
antihypertensive agents was restricted to methyldopa
versus other classes of antihypertensive, and where possi-
ble methyldopa versus b-blockers (Table 5). There was no
difference in incidence of severe hypertension between
agents when methyldopa was compared with other antihy-
pertensive treatments. Two head-to-head studies (86
women) reported incidence of severe hypertension compar-
ing methyldopa and b-blocker antihypertensive treatment:
risk ratio 0.85 (95%CI 0.57-1.37). There was no difference
in the incidence of superimposed pre-eclampsia when
methyldopa was compared with other antihypertensive
agents. There were additionally no signiﬁcant differences
in perinatal outcomes between antihypertensive agents.
Forest plots of these meta-analyses are presented in
Figures 6 and 7.
Discussion
This is the largest systematic review of the evidence from
randomized controlled trials to guide antihypertensive treat-
ment speciﬁcally for chronic hypertension in pregnancy. Other
systematic reviews have pooled results for chronic and
gestational hypertension, but given the different etiology and
Table 2. Continued
Study (First Author, Country,
Year Published) Reason for Exclusion and Study Details
Vigil-De Gracia, Panama,
201465
3-arm pilot study including a third active treatment arm of aspirin
Methods: Randomized open-label pilot trial. Computer-generated code with block size of 6, allocation through sealed
envelopes
Participants: 63 women at <20 weeks’ gestation with systolic BP 90 to 109 mm Hg
Intervention: Furosemide 20 mg once daily vs amlodipine 5 mg once daily vs aspirin 75 mg once daily
Voto, Argentina, 198766 Study participants had gestational or chronic hypertension or pre-eclampsia. Outcomes for those with chronic
hypertension not reported separately
Methods: Randomized open study, no further details given
Participants: 20 women with systolic BP >159 mm Hg and/or diastolic BP >99 mm Hg recorded twice
24 h apart
Intervention: Ketanserin 20 to 80 mg daily vs methyldopa 500 to 2000 mg daily
Wichman, Sweden, 198467 Study participants had gestational and not chronic hypertension
Methods: Randomized placebo-controlled trial. Selective allocation
Participants: 52 women at <37 weeks’ gestation with systolic BP >140 mm Hg or diastolic BP >90 mm Hg
or if there was an elevation of >30 mm Hg systolic or >15 mm Hg diastolic from previous readings
Intervention: Metoprolol 50 mg twice daily vs placebo 1 tablet twice daily
Wide-Swensson, Sweden,
199568
Study participants had gestational and not chronic hypertension
Methods: Randomized parallel double-blind multicenter trial. Block randomization by numbers, allocation by sealed
envelope
Participants: 118 women with singleton pregnancy, gestational age between 25 and 37 weeks and diastolic
BP between >95 and <110 mm Hg
Intervention: Isradipine slow-release 5 mg twice daily vs placebo 1 tablet twice daily
BP indicates blood pressure; IV, intravenous.
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duration of treatment, there are concerns with this approach.
The reduction in the incidence of severe hypertension in
pregnant women with chronic hypertension with the use of
antihypertensive treatment is clinically important given the
short- and long-term associated maternal morbidity and
mortality.8-10,19-21 It is not possible at this time to recommend
one agent over another for optimal blood pressure control, as
there have only been 3 head-to-head randomized controlled
trials enrolling 101 women that have examined this out-
come.32,33,45 No overall reduction in the risk of pre-eclampsia
was seen with the use of antihypertensive treatment.
The paucity of data to guide selection of antihypertensive
treatment for chronic hypertension in pregnancy is also
highlighted. Only 15 randomized controlled trials totaling
1166 pregnancies meeting study eligibility criteria were
identiﬁed, and many of these were too small to address
whether antihypertensive treatments reduce the risk of
superimposed pre-eclampsia or inﬂuence other measures of
perinatal morbidity. The only study published in the last
18 years by Vigil and colleagues compared 3 active treatment
arms and antihypertensive treatments not recommended by
most international guidelines as ﬁrst-line agents (amlodipine,
furosemide, and aspirin).65 It could not be included in the
meta-analysis given this design. This compares with many
more trials and participants outside pregnancy; a recent
systematic review of antihypertensive treatment (excluding
Table 3. Deﬁnitions of Severe Hypertension and Superimposed Pre-Eclampsia for Each Included Study
Study (First Author,
Country, Year) Deﬁnition of Severe Hypertension Deﬁnition of Superimposed Pre-Eclampsia
Arias, USA, 197930 “Pregnancy-aggravated hypertension”: >28 weeks’
gestation diastolic BP >100 mm Hg in 2 consecutive
readings 6 or more h apart
>1+ proteinuria or more than 300 mg/L protein in
24-h collection with “pregnancy-aggravated
hypertension” (see definition of severe hypertension)
Butters, UK, 199031 Not reported Not reported
Fiddler, UK, 198332 Admitted to hospital for hypertension: diastolic BP
>110 mm Hg
Not reported
Freire, Brazil, 198833 Diastolic BP persistently >110 mm Hg Systolic BP increased by 30 mm Hg or diastolic BP
increased by 20 mm Hg for 2 consecutive readings at
least 6 h apart OR proteinuria OR edema
Hirsch, Israel, 199634 Uncontrolled elevation of diastolic BP >100 mm Hg Not reported
Horvath, Australia, 198535 Not reported Not reported
Kahhale, Brazil, 198536 Not reported BP >170/110 mm Hg or proteinuria <37 weeks’
gestation
Mutch, UK, 197737* Systolic BP >170 mm Hg or diastolic BP >110 mm Hg on
2 occasions >4 h apart
Edema, proteinuria from midstream urine in absence of
infection and raised plasma urate
Parazzini, Italy, 199838 Not reported Not reported
Redman, UK, 197639* Systolic BP >170 mm Hg or diastolic BP >110 mm Hg on
2 occasions >4 h apart
Edema, proteinuria from midstream urine in absence of
infection and raised plasma urate
Sibai, USA, 198440 Not reported Not defined but reported as confirmed superimposed
pre-eclampsia
Sibai, USA, 199041 Systolic BP >160 mm Hg or diastolic BP >100 mm Hg Proteinuria (>1 g/24 h) or elevated uric acid (≥6 mg/dL)
during second half of pregnancy
Steyn, South Africa, 199742 Single diastolic BP >120 mm Hg OR 2 consecutive
readings of 110 mm Hg at least 4 h apart
Single diastolic BP >110 mm Hg or 2 consecutive
measurements of 90 mm Hg or more at least 4 h apart
with proteinuria 300 mg/L on 24-h
collection OR 2+ proteinuria on dipstick
Voto, Argentina, 199043 Not reported Additional proteinuria
Weitz, USA, 198744 Not reported Sudden rise in systolic BP >30 mm Hg or diastolic BP
>15 mm Hg and sudden weight gain >2 lb per
week OR proteinuria 2+ or more on dipstick
Welt, USA, 198145 Diastolic BP >100 torr on 2 occasions 6 or more h apart Proteinuria >trace on dipstick or >300 mg/L in
24 h, edema, or both
BP indicates blood pressure.
*Articles reporting the same study population.
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pregnant participants) for the prevention of cardiovascular
disease identiﬁed 123 randomized controlled trials including
613 815 participants.69 Of the 15 studies reported here, only
10 focused on chronic hypertension in pregnancy, and the
other 5 enrolled a mixed population of chronic and gestational
hypertension, from which data for the participants with
chronic hypertension were extracted. Given the changes in
management of hypertension both inside and outside preg-
nancy and that all of these trials were published between
1976 and 1998, optimal antihypertensive therapy for treating
chronic hypertension in pregnancy warrants further investi-
gation through large randomized controlled trials.
Antihypertensive use in pregnancy complicated by chronic
hypertension does not increase the risk of stillbirth or neonatal
death. No reduction in birth weight or increase in small-for-
gestational-age infants was seen, although heterogeneity was
evident. This strengthens the ﬁnding that antihypertensive
agents do not signiﬁcantly affect perinatal morbidity; agent
selection and higher than recommended dose are likely to
account for the evidence from Butters and colleagues, who
published data from a study of 29 participants randomized in
the second trimester to atenolol or placebo.31 Although it is
evident that the results of this study have inﬂuenced clinical
practice,8,17 this appears to be speciﬁc to this agent or to the
very high doses that were used (up to 200 mg daily). Doses
above 50 mg atenolol daily are not recommended and
infrequently used nowadays for hypertension, as above this,
the dose-response curve is typically quite ﬂat for blood-
pressure lowering, with the maximum licensed dose for other
indications being 100 mg daily. The primary results for this
analysis have been presented without the inclusion of this
study for these reasons. Von Dadelszen and colleagues also
analyzed with and without the data from the Butters study
when examining the impact of antihypertensive treatment on
the risk of small-for-gestational-age newborns due to concerns
over trial reporting.16,70
Ten of the 15 studies included in the meta-analysis
evaluated agents that are no longer used for the routine
A
B
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Arias, 1979
Buers, 1990
Fiddler, 1983
Freire, 1988
Hirsch, 1996
Horvath, 1985
Kahhale, 1985
Parazzani, 1998
Redman, 1976*
Sibai, 1984
Sibai, 1990
Steyn, 1997
Voto, 1990
Weitz, 1987
Welt, 1981
Overall risk of bias
Random sequence generaon
Allocaon concealment
Blinding parcipants & personnel
Blinding outcome assessment
Incomplete outcome data
Selecve outcome reporng
Risk of bias items presented as percentages across all included studies
0%                     25%                    50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
Figure 2. Risk-of-bias assessment of each study included in the meta-analysis. A, Risk-of-bias assessment by individual assessment of
criteria for each study. Randomized controlled trials are listed alphabetically by author name. B, Risk-of-bias items presented as
percentages across all included studies. *Redman et al39 and Mutch et al37 both publish data from the same study; only the Redman article
has been assessed for risk of bias. Risk-of-bias summary shows review authors’ judgments about each risk-of-bias domain in randomized
controlled trials on efﬁcacy of antihypertensive treatment for chronic hypertension in pregnancy.
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management of hypertension in pregnancy in many coun-
tries (atenolol, acebutalol, oxprenolol, pindolol, bendroﬂume-
thiazide, hydrochlorothiazide, furosemide) or in the general
nonpregnant population (ketanserin), accounting for about
45% of the participants studied. Although labetalol is
commonly used in pregnancy, not all b-blockers can be
considered equivalent. Labetalol is a racemate with a- and
nonselective b-antagonist activity (in a ratio of around 1 to
3) for oral labetalol.71,72 Oxprenolol, acebutalol, and pindolol
are more selective for b1 receptors than b2 receptors but
are additionally partial agonists, possessing intrinsic sym-
pathomimetic activity (resulting in less effect on reducing
heart rate). Although licensed for hypertension, b-blockers
are no longer recommended as ﬁrst-line antihypertensive
treatment, but are now regarded as fourth line agents for
resistant hypertension in the general (nonpregnant) popula-
tion.73 The dose of bendroﬂumethiazide used (5-10 mg
daily) is higher than that currently used for hypertension
(2.5 mg daily). Therefore, a substantial proportion of the
evidence for treatment of hypertension in pregnancy is
0.1 1 10
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Hirsch (1996) 4/15 6/12 0.53 (0.19, 1.47) 27.27
Steyn (1997) 6/69 17/69 0.35 (0.15, 0.84) 37.01
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Mutch (1977) 4/100 7/102 0.58 (0.18, 1.93) 14.68
Arias (1979) 1/29 3/29 0.33 (0.04, 3.02) 6.36
Welt (1981)* 2/15 0/6 2.19 (0.12, 39.90) 1.47
Sibai (1984) 1/10 1/10 1.00 (0.07, 13.87) 2.12
Weitz (1987) 5/13 4/12 1.15 (0.40, 3.31) 8.81
Sibai (1990)* 30/173 14/90 1.12 (0.62, 1.99) 39.02
Steyn (1997) 2/69 13/69 0.15 (0.04, 0.66) 27.54
Overall  
τ -squared= 0.169
I-squared = 28.1%, 
P = 0.214
45/409 42/318 0.74 (0.49, 1.11) 100.00
Treatment 
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Treatment 
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A
B
Figure 3. Maternal outcomes: active vs nonactive treatment. A, Severe hypertension. B, Superimposed pre-eclampsia. *Where studies had
more than 1 active treatment arm, the data from the active treatment arms were pooled and compared with the non-active-treatment data.
Studies are listed in order of the year they were published. Antihypertensive agents used in each study are listed in Table 1. The numbers of
participants experiencing severe hypertension or superimposed pre-eclampsia in each treatment group are denoted as “n,” with the total
number of participants with chronic hypertension in each study arm denoted as “N.” Forest plots of the meta-analysis for each maternal
outcome: active vs nonactive treatment. The gray rectangles represent the risk ratio for each study and are sized in proportion to the weight
assigned to the study within the analysis. The red dotted line represents to overall risk ratio for each outcome and the lateral tips of the
diamond represent the 95% conﬁdence interval for the summary measure.
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Arias (1979) 4/29 4/29 1.00 (0.28, 3.62) 24.49
Welt (1981) 4/15 0/6 3.94 (0.24, 63.69) 4.26
Sibai (1990) 13/173 8/90 0.85 (0.36, 1.96) 64.44
Hirsch (1996) 1/15 1/12 0.80 (0.06, 11.50) 6.80
Overall  
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P = 0.772
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Figure 4. Perinatal outcomes: active vs nonactive treatment. A, Stillbirth or neonatal death. B, Birth weight. C, Small-for-gestational-age
infants. *Where studies had more than 1 active treatment arm, the data from the active treatment arms were pooled and compared with the
nonactive treatment data. Studies are listed in order of the year they were published. Antihypertensive agents used in each study are listed in
Table 1. The numbers of participants experiencing a stillbirth/neonatal death or small-for-gestational-age infant in each treatment group are
denoted as “n,” with the total number of participants with chronic hypertension in each study arm denoted as “N.” Forest plots of the meta-
analysis for each perinatal outcome: active vs nonactive treatment. The gray rectangles represent the risk ratio for each study and are sized
in proportion to the weight assigned to the study within the analysis. The red dotted line represents to overall risk ratio for each outcome and
the lateral tips of the diamond represent the 95% conﬁdence interval for the summary measure.
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based on outdated drugs and outdated doses. It is difﬁcult
to draw conclusions over the effect of antihypertensive
agents on other maternal and perinatal outcomes. Meta-
analysis of many maternal and fetal secondary outcomes
was not possible due to a lack of reporting in the trials
conducted to date. In addition, the planned adjustment for
potential confounders such as body mass index was not
possible due to inconsistent or absent reporting in the trial
manuscripts. Further studies are needed to answer these
questions and assess the potential impact of maternal
characteristics such as obesity and other medical comor-
bidities.
The Cochrane risk-of-bias assessment was high or unclear
for all the studies included. This is primarily due to
assignment of unclear risk of bias to many areas of study
conduct and restrictions in the Cochrane tool. Many studies
were open-label, assigning them high risk of bias, which
reﬂects the difﬁculties in blinding medication within preg-
nancy when blood pressure is dynamic and multiple dosing
changes are required over a short time period. Additionally,
the studies are not uniform in their reported outcome
measures, which reﬂect the large time frame and variation in
geographical setting of the studies. All studies included are
at least 18 years old, and given the improvements in
standards of clinical care in addition to standards of study
conduct, there is the potential for substantial bias to be
introduced.
Previous meta-analyses of the antihypertensive treatment
of chronic hypertension in pregnancy are smaller than this
study and have focused on other interventions and out-
comes.14,74 The most recent of these was published in
2000. This study aimed to assess long-term treatment of
chronic hypertension in pregnancy, and the majority of trials
did not provide sufﬁcient detail to allow categorization into
mild or severe hypertension. In addition, a considerable
portion of women will cross over from 1 group to the other,
making analysis problematic. A Cochrane review has been
conducted on the use of antihypertensive treatment for
“mild to moderate” hypertension in pregnancy.12 The
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Figure 5. Funnel plot comparing birth-weight difference
between studies. Funnel plot demonstrates that Butters and
colleagues31 (atenolol vs placebo) is an outlier within the meta-
analysis of birth weight when comparing active and nonactive
treatment. Antihypertensive agents used in each study are listed
in Table 1.
Table 4. Summary of Meta-Analysis Findings Comparing Active With Nonactive Treatment and the Effect on Maternal and
Perinatal Outcomes in Pregnancy Complicated by Chronic Hypertension
Outcome
Number of Studies
Reporting Outcome Total Participants
Risk Ratio/Weighted
Mean Difference 95%CI
Degree of
Heterogeneity, I2
Maternal
Severe hypertension 530,34,37,42,45 446 0.33 0.19 to 0.56 0.0%
Superimposed pre-eclampsia 730,37,40-42,44,45 727 0.74 0.49 to 1.11 28.1%
Cesarean section delivery 430,37,40,41 543 1.23 0.92 to 1.63 0.0%
Abruption 241,42 401 0.35 0.10 to 1.27 20.9%
Perinatal
Stillbirth/neonatal death 430,39,41,42 667 0.37 0.11 to 1.26 0.0%
Birth weight, g 730,34,36,38-41 802 60 200 to 80 g 0.0%
Small for gestational age 430,34,41,45 369 1.01 0.53 to 1.94 0.0%
Gestation at delivery, weeks 730,34,39-42,44 785 0.10 0.05 to 0.24 83.7%
Preterm birth 330,40,41 341 1.23 0.58 to 2.54 0.0%
Apgar score <7 at 5 min 434,36,40,41 410 1.13 0.40 to 3.20 0.0%
Risk ratios provided where binary data were analyzed, and weighted mean difference given for continuous outcomes.
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authors conclude “whether the reduction in the risk of
severe hypertension is considered sufﬁcient to warrant
treatment is a decision that should be made by women in
consultation with their obstetrician” and classed “mild to
moderate” hypertension as a systolic blood pressure up to
and including 169 mm Hg. In contrast, the Control of
10.1 10
Study, 
First Author, Year
Methyldopa,
n/N
Other anhypertensive 
agents, 
n/N
Forest plot Risk Rao 
(95% Conﬁdence 
Interval)
% 
Weight
Welt (1981) 0/6 1/9 0.48 (0.02, 10.1) 5.73
Fidler (1983) 11/22 14/24 0.86 (0.50, 1.47) 59.98
Freire (1988) 9/20 4/20 2.25 (0.83, 6.13) 34.29
Overall  
-squared = 0.172
I-squared = 36.4%, 
P = 0.208
20/48 19/53 1.13 (0.71, 1.81) 100.00
Treatment 
reduces risk
Treatment 
increases risk
Study, 
First Author, Year
Methyldopa,
n/N
Other anhypertensive 
agents, 
n/N
Forest plot Risk Rao 
(95% Conﬁdence 
Interval)
% 
Weight
Welt (1981) 0/6 2/9 0.29 (0.02, 5.08) 7.43
Freire (1988) 4/20 3/20 1.33 (0.34, 5.21) 10.83
Sibai (1990) 16/87 14/86 1.13 (0.59, 2.17) 50.81
Voto (1990) 6/21 10/28 0.80 (0.35, 1.85) 30.93
Overall  
-squared = 0.0
I-squared = 0.0%, 
P = 0.728
26/134 29/143 0.99 (0.62, 1.58) 100.00
10.1 10
Treatment 
reduces risk
Treatment 
increases risk
A
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τ
τ
Figure 6. Maternal outcomes: comparison of methyldopa vs other antihypertensive agents. A, Severe hypertension. B, Superimposed
pre-eclampsia. Studies are listed in order of the year they were published. Antihypertensive agents used in each study are listed in
Table 1. The number of participants experiencing severe hypertension or superimposed pre-eclampsia in each treatment group are
denoted as “n,” with the total number of participants with chronic hypertension in each study arm denoted as “N.” Forest plots of the
meta-analysis for each maternal outcome: comparison of methyldopa vs other antihypertensive agents. The gray rectangles represent the
risk ratio for each study and are sized in proportion to the weight assigned to the study within the analysis. The red dotted line represents
to overall risk ratio for each outcome and the lateral tips of the diamond represent the 95% conﬁdence interval for the summary measure.
Table 5. Summary of Meta-Analysis Findings Comparing Methyldopa With Other Antihypertensive Agents and the Effect on
Maternal and Perinatal Outcomes in Pregnancy Complicated by Chronic Hypertension
Outcome
Number of Studies
Reporting Outcome Total Participants
Risk Ratio/Weighted
Mean Difference 95%CI
Degree of
Heterogeneity, I2
Maternal
Severe hypertension 332,33,45 101 1.13 0.71 to 1.81 36.4%
Superimposed pre-eclampsia 433,41,43,45 277 0.99 0.62 to 1.58 0.0%
Perinatal
Stillbirth/neonatal death 235,41 186 2.24 0.35 to 14.28 0.0%
Birth weight, g 332,33,41 259 50 200 to 290 0.0%
Risk ratios provided where binary data were analyzed, and weighted mean difference given for continuous outcomes.
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Hypertension in Pregnancy Study concludes that “tight
control” of blood pressure should be recommended to
reduce the risk of short- and long-term maternal morbidity
given that this does not affect fetal or neonatal outcome
adversely.18,22 Subgroup analyses of those with chronic
hypertension suggest a possible trend toward small for
gestational age, birth weight <10th centile (13.9% versus
19.7%; adjusted odds ratio 0.66, 95%CI 0.44-1.00); however,
it is notable that in this subgroup the primary perinatal
outcome was no different (odds ratio 1.08, 95%CI 0.78-
1.51). A post hoc analysis of the Control of Hypertension in
Pregnancy Study found that severe hypertension occurring in
either intervention group (tight versus less-tight control) was
associated with higher rates of pregnancy loss, neonatal unit
admission, and birth weight <10th centile,22 suggesting a
perinatal beneﬁt to reducing the risk of severe hypertension.
Additionally, those with severe hypertension in the less-tight
control group were found to have an increased risk of
serious maternal morbidity/mortality (odds ratio 3.74, 95%CI
1.25-11.22).22 Although some still question the need to treat
hypertension before it reaches severe levels, the American
Heart Association and the American Stroke Association
recommend systolic blood pressure should be treated above
the level of 150 mm Hg to reduce the risk of stroke.75 This
recommendation is echoed in the ﬁndings of the UK triennial
enquiry into maternal death, which found severe hyperten-
sion to be a factor in a signiﬁcant proportion of hyperten-
sion-related deaths.9 Of note, since this recommendation,
deaths from pre-eclampsia have fallen to less than 1 per
million in the UK.76
Study, 
First Author, Year
Methyldopa,
n/N
Other anhypertensive
agents, 
n/N
Forest plot Risk Rao 
(95% Conﬁdence 
Interval)
% 
Weight
Horvath (1985) 1/5 0/11 6.0 (0.29, 126.30) 45.00
Sibai (1990) 1/87 1/86 0.99 (0.06, 15.55) 55.00
Overall  
-squared= 0.0
I-squared = 0.0%, 
P = 0.39
2/92 1/97 2.24 (0.35, 14.28) 100.00
Treatment 
reduces risk
Treatment 
increases risk
0.1 1 10
Study, 
First Author, Year
Methyldopa,
mean birth weight, g
β-blockers*, 
mean birth weight, g
Forest plot Weighted mean 
diﬀerence, g
(95% Conﬁdence 
Interval)
% 
Weight
Fidler (1983) 2992 2715 330 (-251, 914) 17.53
Freire (1988) 3150 3050 31 (-589, 651) 15.49
Sibai (1990) 3051 3068 -25 (-323, 273) 66.98
Overall  
-squared= 0.0
I-squared = 0.0%, 
P = 0.564
46 (-198, 290) 100.00
0-1000g 1000g
Treatment reduces 
birth weight
Treatment increases 
birth weight
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τ
τ
Figure 7. Perinatal outcomes: comparison of methyldopa vs other antihypertensive agents. A, Stillbirth and neonatal death. B, Birth
weight. *Comparison made between methyldopa and beta-blockers as these were the only agents used in head-to-head trials reporting
birth weight. Studies are listed in order of the year they were published. Antihypertensive agents used in each study are listed in Table 1.
The number of participants experiencing a stillbirth/neonatal death in each treatment group are denoted as “n,” with the total number of
participants with chronic hypertension in each study arm denoted as “N.” Forest plots of the meta-analysis for each perinatal outcome:
comparison of methyldopa vs other antihypertensive agents. The gray rectangles represent the risk ratio for each study and are sized in
proportion to the weight assigned to the study within the analysis. The red dotted line represents to overall risk ratio for each outcome and
the lateral tips of the diamond represent the 95% conﬁdence interval for the summary measure.
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The potential effects of “less-tight control” on long-term
maternal morbidity and mortality have recently been high-
lighted.19,20 The Systolic Blood Pressure Intervention Trial
stopped recruitment early due to the signiﬁcant 25% reduc-
tion seen in a composite cardiovascular outcome (stroke,
myocardial infarction, and cardiac failure) with tighter control
of systolic hypertension to a target of 120 mm Hg rather than
the standard treatment target of 140 mm Hg; however, this
was coupled with a signiﬁcant increase in serious adverse
events such as hypotension, syncope, and acute kidney
injury.77 Women of reproductive age with chronic hyperten-
sion are at substantially increased risk of cardiovascular
morbidity and mortality.78 Reducing the incidence of severe
hypertension and maintaining tighter blood pressure control
in pregnancy might contribute to lowering their long-term
cardiovascular risk and warrant further investigation.
Earlier systematic reviews have focused on magnitude of
initial hypertension rather than the underlying condition
causing the hypertension. However, separating chronic and
gestational hypertension, given the differing pathophysiolog-
ical pathways and implications of treatment, allows focus on
optimizing treatment for each condition and is much more
relevant to clinical practice.12,13 Advances in the understand-
ing of the mechanisms behind the exacerbation of hyperten-
sion in pregnancy and the associated increased risk of
superimposed pre-eclampsia should be complemented with
randomized controlled trials that examine how antihyperten-
sive treatment may need to be tailored to the underlying
pathophysiology. The International Society for the Study of
Hypertension in Pregnancy guidelines classifying subtypes of
hypertension in pregnancy have been reﬁned over time, and
head-to-head randomized controlled trials comparing antihy-
pertensive agents speciﬁcally for the treatment of chronic
hypertension in pregnancy using these deﬁnitions are urgently
needed.79
There is emerging evidence that tighter control of hyper-
tension outside pregnancy reduces risks of long-term cardio-
vascular morbidity and mortality.77 In light of the Control of
Hypertension In Pregnancy Study data suggesting fetal safety
with tighter control of hypertension, future research should
focus on head-to-head randomized controlled trials of the
most commonly used antihypertensive agents in current
practice; this should include smaller trials to evaluate efﬁcacy
and larger trials to assess effectiveness of agent(s) for control
of chronic hypertension in pregnancy. In addition, further
consideration of the impact of maternal demographic factors
should be considered such as body mass index and ethnicity.
Outside pregnancy, calcium-channel blockers are recom-
mended as ﬁrst-line antihypertensive therapy for those of
African or Caribbean family origin73; this is due to differing
pathophysiological pathways causing hypertension that vary
with ethnic origin.80 It is possible that the efﬁcacy of
antihypertensive treatment is similarly affected by maternal
ethnic background. This systematic review provides evidence
to recommend that women with chronic hypertension in
pregnancy should receive antihypertensive treatment to
reduce the incidence of severe hypertension and its associ-
ated maternal morbidity without adversely affecting perinatal
outcome.
Conclusions
Antihypertensive treatment reduces the risk of severe hyper-
tension in pregnant women with chronic hypertension. A
considerable paucity of data exists from randomized controlled
trials to guide choice of antihypertensive agent for chronic
hypertension in pregnancy. Adequately powered head-to-head
randomized controlled trials of the commonly used antihyper-
tensive agents are required to inform prescribing.
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SUPPLEMENTAL MATERIAL 
Data S1.
Study Protocol 
INTRODUCTION 
Chronic hypertension (CHT) is estimated to affect up to 2-3% of UK pregnancies. This figure is set to 
increase with an ageing maternal population and the rise in obesity. Pregnancies complicated by 
CHT are associated with an increased risk of adverse outcomes for mother and baby. It is unclear if 
outcomes can be altered through choice of antihypertensive agent. 
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OBJECTIVES 
To perform a systematic review of randomised controlled trials (RCTs) to answer the following 
questions:  
In women with chronic hypertension in pregnancy: 
 Which anti-hypertensive treatment is associated with fewest episodes of severe
hypertension in pregnancy?
 Does frequency of adverse maternal outcomes (e.g. pre-eclampsia, stroke, death) and mode
of delivery vary by antihypertensive agent?
 Does frequency of fetal and neonatal adverse outcomes (e.g. growth restriction, preterm
delivery, neonatal unit admission) vary by antihypertensive agent?
METHODS 
Population 
The population is pregnant women diagnosed with chronic hypertension prior to pregnancy or 
diagnosed up to 20 weeks’ gestation. The definitions of chronic hypertension used by each study will 
be tabulated. Where chronic hypertension is not described the study will be excluded. Both primary 
and secondary chronic hypertension will be included. Studies with intention to treat chronic 
hypertension, regardless of level of hypertension at study entry, will also be included. Studies in 
which participants had gestational hypertension (GH) or chronic hypertension will only be included if 
the data for the chronic hypertension population are reported separately. 
Types of Intervention 
 Any antihypertensive drug compared with alternative intervention (e.g. bed rest) or placebo
 One antihypertensive versus another antihypertensive drug
Eligibility criteria (Published and unpublished RCTs in any language will be assessed for eligibility) 
 Pregnant women with chronic hypertension randomised to antihypertensive treatment arm
and compared prospectively with at least one other treatment arm
 Definition of chronic hypertension reported
Exclusion criteria 
 Any trial designs other than RCT.
 Studies not separating outcome data of participants with gestational or chronic
hypertension
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Outcomes of interest 
Primary outcomes:  
 Maternal
o Severe hypertension (defined as SBP>160mmHg and/or DBP>110mmHg or as given
in paper, with tabulated definitions)
 Fetal/Neonatal
o Birthweight
Secondary outcomes: 
 Maternal
o Superimposed pre-eclampsia (with tabulated definitions)
o Need for additional antihypertensive agent during pregnancy (enteral or parenteral)
o Caesarean section delivery
o Estimated blood loss at delivery
o Eclampsia
o HELLP syndrome (with tabulated definitions)
o Placental abruption
o Other severe maternal morbidity: Disseminated Intravascular Coagulation, Acute
Kidney Injury, Acute Liver Injury, Stroke etc.
o Intensive Therapy Unit/High Dependency Unit admission nights
o Maternal death
o Adverse events and drug side effects, including numbers withdrawn from each trial
and reasons why (if available)
 Fetal/Neonatal:
o Fetal loss: Miscarriage if <24 weeks’ gestation, Stillbirth >24 weeks’ gestation (or as
defined)
o Neonatal Death (death within the first 28 days of life)
o Preterm birth (<37 weeks and subdivided into <34 weeks wherever possible)
o Small for gestational age (SGA) babies (subdivided into birth centiles <10th centile,
<3rd centile where possible)
o APGAR score at 5 minutes
o Arterial cord pH
o Neonatal unit admission
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o Any neonatal morbidity thought to be related to maternal antihypertensive
treatment such as hypo/hypertension, hypoglycaemia, etc.
The primary outcomes have been chosen to answer the principal research question: which anti-
hypertensive(s) treatment is associated with fewest episodes of severe hypertension in pregnancy? 
The secondary outcomes have been chosen to demonstrate any differences in maternal/fetal or 
neonatal outcome based on antihypertensive treatment.  
Search strategy 
The following databases will be searched: 
- Medline (via OVID)
- Embase (via OVID)
- Cochrane Trials Register
Databases will be searched from their earliest entries until 30th April 2015. No language restriction 
will be used in searches. Searches will be adapted to each database and details of each planned 
strategy are listed in the appendix.  
In addition, any currently registered relevant clinical trials will be searched for via:   
- Clinicaltrials.gov
- ISRCTN.com
Other grey literature will be sought by reviewing thesis titles from WorldCat Dissertations and 
Theses database.  
Study records and data extraction 
The titles and abstracts generated from the database searches will be independently screened by 
two authors. If either author considers the study to meet inclusion criteria it will be included for full 
text assessment. Any disagreements will be resolved by involving a third independent reviewer. Any 
foreign language trials will be translated. Data from eligible trials will be manually extracted and 
entered into a standard extraction table independently by the two primary reviewers. Data from all 
studies will then be collectively tabulated. Where there is lack of clarity in data or study design, 
every effort will be made to contact the authors of the RCT for further information.  
Study quality assessment 
Each individual RCT will be quality assessed by one author using the Cochrane Collaboration Risk of 
Bias tool and then checked by a second author. Where there are any disagreements, they will be 
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resolved by discussion with a third author. The following areas of each study will be considered for 
bias: 
 Sequence generation
 Allocation concealment
 Blinding of participants, personnel and outcome assessors
 Incomplete outcome data
 Selective outcome reporting
 Any other sources of bias (including funding source)
Sub-group analysis will be performed based on this quality assessment. 
Data will be collected and tabulated on: 
- Definition of chronic hypertension
- Clinical outcomes of interest as defined
- Criteria specified by Risk of Bias Tool
- Funding source
Data synthesis 
The review will be performed in line with PRISMA guidelines. For all outcomes, the analysis will be 
conducted on an intention to treat basis. If a study contains only per-protocol data for a particular 
endpoint, it will be excluded from the main analysis. Meta-analysis will be undertaken where there is 
more than one study with analysable data. When there is only one study, the estimates from that 
study will be presented. Treatment effects will be presented as estimated differences in the mean or 
odds ratios with 95% confidence intervals.  In the event of important significant treatment effects, 
the Number Needed to Treat (NNT) or Number Needed to Harm (NNH) will also be given.  
Conventional significance will be at the usual 5% level (2-sided). 
Heterogeneity of results between studies will be tested using a Chi2 test. Significant heterogeneity 
will be assessed using Tau2 and by visual inspection of the forest plot. Where there are sufficient 
studies of different populations, entry criteria or treatments, meta-regression and subgroup analysis 
will be used to investigate the differences between study results.  Meta-regression will be 
performed with reported variables that are suspected to influence efficacy of treatment. Subgroup 
analysis will be performed by:  
 Ethnicity
 Age
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 BMI
 Quality
Publication bias will be investigated using Egger’s test and funnel plots. 
Where data collected are insufficient for quantitative synthesis, they will be tabulated for 
presentation and explored in the discussion. If outcomes of interest are not able to be quantitatively 
synthesised, recommendations for the definitive trial to obtain these data will be made in the study 
conclusions.   
Confidence in cumulative evidence 
For each outcome of interest, the quality of the body of evidence will be assessed using the Grading 
of Recommendations Assessment, Development and Evaluation (GRADE) system, in line with 
recommendations from the GRADE working group. Quality of evidence will be determined as high, 
moderate, low or very low through assessing: risk of bias, directness, consistency of results, 
precision, publication bias, magnitude of effect, and dose-response relationship. Confidence of the 
effect size of intervention on outcomes of interest will be based on this assessment. 
APPENDIX 
a. Search strategy for Medline (via OVID platform)
1. exp Hypertension/
2. exp Pregnancy/
3. exp Cardiovascular Agents/
4. 1 and 2 and 3
5. randomized controlled trial.pt.
6. controlled clinical trial.pt.
7. randomized.ab.
8. placebo.ab.
9. randomly.ab.
10. clinical trials as topic.sh.
11. trial.ti.
12. 5 or 6 or 7 or 8 or 9 or 10 or 11
13. exp animal/ not humans.sh.
14. 12 not 13
15. 4 and 14
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b. Search strategy for Embase (via OVID platform)
1. exp hypertension/
2. exp pregnancy/
3. exp antihypertensive agent/
4. 1 and 2 and 3
5. random$.ab.
6. factorial$.ab.
7. crossover$.ab.
8. placebo$.ab.
9. (doubl$ adj blind$).ab.
10. (singl$ adj blind$).ab.
11. assign$.ab.
12. allocat$.ab.
13. volunteer$.ab.
14. crossover procedure/
15. double blind procedure/
16. single blind procedure/
17. exp controlled clinical trial/
18. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19. 4 and 18
c. Search strategy for Cochrane Library
pregnancy AND hypertension AND antihypertensive 
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